EpiBench: Can LLMs Understand Epitopes for Antibody Drug Discovery?

The 30-second take

• What: Epitopes determine where antibodies bind antigens and shape downstream therapeutic properties such as functional blockade and escape resistance, making epitope understanding centra
• Why now: Biotech & Longevity is active on arXiv; heuristic disruptiveness 49/100.
• Who should care: Researchers and builders tracking Biotech & Longevity.

What the paper actually did

The authors present EpiBench: Can LLMs Understand Epitopes for Antibody Drug Discovery? (arXiv:2608.06022).

Epitopes determine where antibodies bind antigens and shape downstream therapeutic properties such as functional blockade and escape resistance, making epitope understanding central to antibody drug discovery. Although large language models (LLMs) have shown strong biomedical reasoning ability, it remains unclear whether they can infer epitope information directly from antigen and antibody sequences.

Existing epitope resources typically focus on isolated prediction tasks or rely on specialized structural settings, while general protein benchmarks do not evaluate epitope-centered decisions across the antibody development workflow. To address this gap, we introduce EpiBench, a closed-book, sequence-based, and automatically scorable benchmark for evaluating epitope reasoning in LLMs. EpiBench contains 1,609 curated samples grounded in structural antibody--antigen contacts, curated functional B-cell assays, and deep mutational scanning escape measurements.

Categories: cs.CL, q-bio.GN. Authors: Zirui Wang, Jiaqi Wang, Qinghan Wang, Yuzhi Xu, Gang Du, Tingjun Hou, Odin Zhang.

What makes this disruptive

We score this 49/100 (novelty 60, impact 50, field heat 45, practicality 65, controversy 25).

Heuristic score based on topical heat terms (0 hits) and claim-language signals. Editorial review recommended before publish.

If the core claim holds, it can shift priorities in Biotech & Longevity — treat this as a roadmap signal, not a final verdict.

Why it matters (outside the lab)

Shifts in Biotech & Longevity cascade into research agendas, tooling choices, and funding theses.

Near-term: compare the preprint’s setup and baselines to your internal work before over- or under-weighting it.

Medium-term: replication, open data/code, and follow-on preprints decide whether this becomes a durable line of work.

Limitations & open questions

Heuristic explainer caveats (no LLM rewrite):

- Preprint: Not peer-reviewed by us; claims are provisional. - Scope: Read the PDF for exact tasks, datasets, and hardware. - No independent replication: We have not re-run experiments (arXiv:2608.06022). - Scoring is automated: Disruptiveness uses rule-based heat terms until editorial/AI review.